These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12476272)

  • 1. Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
    Nelson RP; Logan TF; Abonour R
    Bone Marrow Transplant; 2002 Dec; 30(12):805-12. PubMed ID: 12476272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-myeloablative allogenic peripheral blood stem cell transplantation for treatment of advanced renal cell carcinoma].
    Konaka H; Takami A; Koshida K; Nakao S; Namiki M
    Hinyokika Kiyo; 2005 Aug; 51(8):503-7. PubMed ID: 16164264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma.
    Childs RW
    Crit Rev Immunol; 2001; 21(1-3):191-203. PubMed ID: 11642604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nonmyeloablative allogeneic peripheral blood stem cell transplantation of renal cell carcinoma].
    Namiki M; Takami A; Koshida K; Nakao S
    Nihon Rinsho; 2003 Sep; 61(9):1607-12. PubMed ID: 14515732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer.
    Arya M; Chao D; Patel HR
    Nat Clin Pract Oncol; 2004 Nov; 1(1):32-8. PubMed ID: 16264797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice.
    Harano M; Eto M; Iwai T; Tatsugami K; Kiyoshima K; Kamiryo Y; Tsuneyoshi M; Yoshikai Y; Naito S
    Cancer Res; 2005 Nov; 65(21):10032-40. PubMed ID: 16267029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
    van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
    Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.
    Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S
    Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
    Rini BI; Halabi S; Barrier R; Margolin KA; Avigan D; Logan T; Stadler WM; McCarthy PL; Linker CA; Small EJ; ; ;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):778-85. PubMed ID: 16785067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies.
    Kami M; Makimoto A; Heike Y; Takaue Y
    Jpn J Clin Oncol; 2004 Dec; 34(12):707-16. PubMed ID: 15640500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
    Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T
    Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: first evidence of cord-blood-versus-solid-tumor effect.
    Takami A; Takamatsu H; Yamazaki H; Ishiyama K; Okumura H; Ohata K; Konaka H; Asakura H; Namiki M; Nakao S
    Bone Marrow Transplant; 2006 Dec; 38(11):729-32. PubMed ID: 17028623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].
    Cheng YC; Ueno NT
    Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma.
    Takahashi Y; Childs RW
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6353S-9S. PubMed ID: 15448030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
    Rzepecki P; Zolnierek J; Sarosiek T; Langiewicz P; Szczylik C
    Neoplasma; 2005; 52(3):238-42. PubMed ID: 15875086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation for patients with metastatic renal cell carcinoma.
    Roigas J; Johannsen M; Ringsdorf M; Massenkeil G
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1449-58. PubMed ID: 17069529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
    Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
    Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.